Clinical Commander

Back to dossier
cardio.cardiogenic-shock.acute-mitral-regurgitation.v1PRODUCTION
cardio.cardiogenic-shock.acute-mitral-regurgitation.v1

Cardiogenic shock — acute severe mitral regurgitation

cardiologyacuteadult
Hard-required inputs
0 / 15
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm acute severe MR as the cardiogenic shock etiology — sudden flash pulm edema + new holosystolic murmur + biventricular dysfunction; identify suspected sub-etiology (post-MI papillary rupture vs chordal rupture vs endocarditis vs trauma vs iatrogenic) which drives surgical urgency

Inputs
2
Actions
0
Advance rule
Set
Advance when

Acute severe MR confirmed and sub-etiology hypothesis stated

Patient inputs (18)

GOLD STANDARD — ruptured papillary muscle visualization, vena contracta ≥0.7 cm, EROA ≥0.4 cm², regurgitant volume ≥60 mL, mechanism (rupture vs perforation vs flail), surgical planning

Coronary angiography for ischemic etiology — culprit lesion identification + revascularization assessment if MI-related papillary rupture

Older patients (post-MI papillary rupture, degenerative MVP) over-represented; informs surgical-risk stratification + TEER candidacy

Sinus tachycardia maintains compensatory forward flow; AF / new arrhythmia worsens hemodynamics by losing atrial contribution and shortening diastolic filling

End-organ damage marker + dose adjustment for diuretics + nitrate; contrast nephropathy risk for cath/CTA

Day 2-7 post-MI is highest risk window for papillary muscle rupture; inferior MI ruptures POSTEROMEDIAL PM (single PDA blood supply)

Flash pulmonary edema severity tracker; intubation often needed

Elevated if etiology is post-MI papillary rupture; trend tracks ongoing ischemia

Acute volume overload marker; trend tracks decongestion + recovery

Active endocarditis is a major etiology of acute MR; obtain × 3 sets before any antibiotics

Bedside TTE for initial screen — flail leaflet, eccentric jet, biventricular function; PRELIMINARY only — TEE is gold standard

Recent or active inferior / inferoposterior MI (papillary rupture); AF; LV strain pattern

Flash pulmonary edema with normal-sized cardiac silhouette is cardinal differentiator from chronic decompensated MR

SCAI 2022 staging baseline; gates vasopressor escalation; SBP <90 with flash pulm edema is the cardinal acute MR + CS presentation

SCAI 2022 staging + response to therapy; CardShock prognostication (Harjola EHJ 2015 PMID 26333869)

Pre-existing degenerative MVP predisposes to spontaneous chordal rupture

Blunt chest trauma → leaflet tear / papillary avulsion

Recent TAVR / MitraClip / balloon valvuloplasty / surgical valve manipulation

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningpapillary_muscle_rupture_confirmed_on_tee
    STAT TEE confirms papillary muscle rupture (most often posteromedial PM after inferior MI) — mortality ≥80% medical vs <10% surgical (Thompson SHOCK trial sub-analysis)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningiabp_bridge_failure_in_acute_severe_mr
    IABP placed but persistent shock + worsening lactate + refractory pulm edema → expedite surgery; consider VA-ECMO if surgery not immediately available
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningendocarditis_with_acute_mr_and_sepsis_overlap
    Active infective endocarditis (S. aureus, Strep) + acute severe MR + CS + concurrent sepsis — emergent surgery indication despite operative risk; balance source control vs sepsis stabilization
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereteer_mitraclip_decision_for_prohibitive_surgical_risk
    Acute severe MR + CS in patient with prohibitive surgical risk (STS >15%, severe frailty, multi-organ failure) — TEER (MitraClip) salvage option per Estévez-Loureiro IREMMI 2024
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereflash_pulmonary_edema_refractory_to_diuretic
    Refractory flash pulmonary edema in acute severe MR despite IV nitrate + diuretic + IABP — intubation needed; expedite surgery
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Acute severe MR + CS — emergent surgery + IABP bridge (preferred MCS) + cautious inotrope + diuretic + afterload reduction; AVOID isolated vasoconstrictor
axis: acute_severe_mr_cs_phenotype
Selected axis "Acute severe MR + CS — emergent surgery + IABP bridge (preferred MCS) + cautious inotrope + diuretic + afterload reduction; AVOID isolated vasoconstrictor" by default fallback (first axis)
  • norepinephrine
    first line
    vasopressor_alpha
    0.05–0.5 µg/kg/min titrate MAP ≥65 • IV • continuous
    triggers: acute_severe_mr_cs_with_sbp_lt_90, cs_scai_c_or_higher
    SOAP-II PMID 20200382 — NE first-line in CS; CAUTION — pair with afterload reduction in acute MR to prevent worsening regurgitant fraction
    rxcui 7512
  • dobutamine
    second line
    inotrope_beta1
    2.5 µg/kg/min CAUTIOUS titration • IV • continuous
    triggers: low_cardiac_output_despite_NE_and_iabp, no_active_arrhythmia
    DOREMI PMID 33704937 — non-inferior to milrinone; CAUTION in acute MR (may worsen MR severity by increasing LV contractility)
    rxcui 3616
  • sodium nitroprusside
    first line
    arteriovenodilator
    0.25–0.5 µg/kg/min start; titrate to MAP 65–75 • IV • continuous
    triggers: acute_severe_mr_with_pulm_edema_and_adequate_map, need_afterload_reduction
    Cornerstone afterload reduction in acute severe MR — reduces regurgitant fraction + improves forward flow + reduces pulmonary edema; cyanide accumulation risk if eGFR <30
    rxcui 9895
  • nitroglycerin
    first line
    venodilator
    5–20 µg/min titrate up to 200 µg/min • IV • continuous
    triggers: flash_pulmonary_edema_in_acute_mr, preload_reduction_needed
    Preload reduction → reduces PCWP + V-wave + pulm edema; first-line decongestant in acute MR with preserved MAP
    rxcui 4917
  • furosemide
    first line
    loop_diuretic
    40–80 mg IV bolus then infusion 5–10 mg/h • IV • bolus + continuous
    triggers: flash_pulmonary_edema, volume_overload_with_adequate_perfusion
    Decongest after perfusion stable (ESC 2021 HF Guidelines); continuous infusion preferred for refractory pulm edema
    rxcui 4603
  • vasopressin
    add on
    V1_agonist
    0.03 U/min fixed • IV • continuous
    triggers: NE_above_0.5_with_persistent_hypotension
    V1-mediated; pulmonary-vascular sparing; adjunct to NE when acute MR + RV failure overlap
    rxcui 11149
  • vancomycin
    first line
    glycopeptide_antibiotic
    25–30 mg/kg IV load then 15–20 mg/kg q12h adjusted to trough 15–20 • IV • q12h
    triggers: endocarditis_suspected_in_acute_mr, awaiting_blood_culture_results
    AHA 2015 endocarditis guideline empiric coverage for native valve endocarditis — gram-positive cocci dominant pathogen spectrum
    rxcui 11124
  • ceftriaxone
    first line
    cephalosporin_3rd_gen
    2 g IV q24h • IV • q24h
    triggers: endocarditis_suspected_in_acute_mr, awaiting_blood_culture_results
    AHA 2015 endocarditis guideline empiric coverage — covers Streptococcus + HACEK organisms
    rxcui 2193
  • warfarin
    first line
    vitamin_k_antagonist
    Post-op: 5 mg daily; mechanical mitral INR target 2.5–3.5; bioprosthetic INR 2–3 × 3 mo then ASA • PO • daily
    triggers: mechanical_mitral_valve_post_op, bioprosthetic_mitral_valve_first_3_mo
    ACC/AHA 2020 valvular Class I — mechanical mitral valve requires lifelong warfarin INR 2.5–3.5; bioprosthetic INR 2–3 × 3 mo then ASA chronic
    rxcui 11289

outpatient playbook — drug actions (4)

  1. 1. continue warfarin lifelong (mechanical) or × 3 mo (bioprosthetic)
    rxcui 11289
    INR 2.5–3.5 mechanical / 2–3 × 3 mo bioprosthetic • PO • daily
    trigger: Post-op valve replacement
    ACC/AHA 2020 valvular Class I — lifelong for mechanical, 3 mo + ASA chronic for bioprosthetic
  2. 2. continue or up-titrate GDMT 4-pillar if persistent EF<40
    lisinopril or sac/val + carvedilol + MRA + SGLT2i • PO • daily/BID
    trigger: Persistent EF<40
    AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499)
  3. 3. continue aspirin 81 mg if bioprosthetic
    rxcui 243670
    81 mg PO daily • PO • daily
    trigger: Bioprosthetic MV
    ACC/AHA 2020 valvular Class IIa lifelong
  4. 4. amoxicillin 2 g 30-60 min before dental procedures
    2 g PO • PO • before procedure
    trigger: Prosthetic valve + dental procedure with bleeding risk
    AHA 2007 endocarditis prophylaxis

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Sudden flash pulmonary edema + hemodynamic deterioration → acute severe MR with CS until proven otherwise; STAT TEE: ruptured papillary muscle / flail leaflet / vena contracta ≥0.7 cm / EROA ≥0.4 cm² + biventricular dysfunction + shock physiology; Recent inferior / inferoposterior MI (24-168 h prior) + new harsh holosystolic murmur at apex + flash pulmonary edema → posteromedial papillary muscle rupture.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — acute severe mitral regurgitation** (cardio.cardiogenic-shock.acute-mitral-regurgitation.v1).
Scope: Confirm acute severe MR as the cardiogenic shock etiology — sudden flash pulm edema + new holosystolic murmur + biventricular dysfunction; identify suspected sub-etiology (post-MI papillary rupture vs chordal rupture vs endocarditis vs trauma vs iatrogenic) which drives surgical urgency

No severity triggers fired against current inputs.

Plan

Regimen axis: **Acute severe MR + CS — emergent surgery + IABP bridge (preferred MCS) + cautious inotrope + diuretic + afterload reduction; AVOID isolated vasoconstrictor**.
1. norepinephrine 0.05–0.5 µg/kg/min titrate MAP ≥65 IV continuous (vasopressor_alpha, first line) — SOAP-II PMID 20200382 — NE first-line in CS; CAUTION — pair with afterload reduction in acute MR to prevent worsening regurgitant fraction
2. dobutamine 2.5 µg/kg/min CAUTIOUS titration IV continuous (inotrope_beta1, second line) — DOREMI PMID 33704937 — non-inferior to milrinone; CAUTION in acute MR (may worsen MR severity by increasing LV contractility)
3. sodium nitroprusside 0.25–0.5 µg/kg/min start; titrate to MAP 65–75 IV continuous (arteriovenodilator, first line) — Cornerstone afterload reduction in acute severe MR — reduces regurgitant fraction + improves forward flow + reduces pulmonary edema; cyanide accumulation risk if eGFR <30
4. nitroglycerin 5–20 µg/min titrate up to 200 µg/min IV continuous (venodilator, first line) — Preload reduction → reduces PCWP + V-wave + pulm edema; first-line decongestant in acute MR with preserved MAP
5. furosemide 40–80 mg IV bolus then infusion 5–10 mg/h IV bolus + continuous (loop_diuretic, first line) — Decongest after perfusion stable (ESC 2021 HF Guidelines); continuous infusion preferred for refractory pulm edema
6. vasopressin 0.03 U/min fixed IV continuous (V1_agonist, add on) — V1-mediated; pulmonary-vascular sparing; adjunct to NE when acute MR + RV failure overlap
7. vancomycin 25–30 mg/kg IV load then 15–20 mg/kg q12h adjusted to trough 15–20 IV q12h (glycopeptide_antibiotic, first line) — AHA 2015 endocarditis guideline empiric coverage for native valve endocarditis — gram-positive cocci dominant pathogen spectrum
8. ceftriaxone 2 g IV q24h IV q24h (cephalosporin_3rd_gen, first line) — AHA 2015 endocarditis guideline empiric coverage — covers Streptococcus + HACEK organisms
9. warfarin Post-op: 5 mg daily; mechanical mitral INR target 2.5–3.5; bioprosthetic INR 2–3 × 3 mo then ASA PO daily (vitamin_k_antagonist, first line) — ACC/AHA 2020 valvular Class I — mechanical mitral valve requires lifelong warfarin INR 2.5–3.5; bioprosthetic INR 2–3 × 3 mo then ASA chronic

Setting playbook (outpatient) — 1 mo + 3 mo + 6 mo + annual valve clinic surveillance — confirm valve function + LV recovery + INR control + GDMT optimization + endocarditis prophylaxis + lifelong follow-up
10. continue warfarin lifelong (mechanical) or × 3 mo (bioprosthetic) INR 2.5–3.5 mechanical / 2–3 × 3 mo bioprosthetic PO daily — Post-op valve replacement (ACC/AHA 2020 valvular Class I — lifelong for mechanical, 3 mo + ASA chronic for bioprosthetic)
11. continue or up-titrate GDMT 4-pillar if persistent EF<40 lisinopril or sac/val + carvedilol + MRA + SGLT2i PO daily/BID — Persistent EF<40 (AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499))
12. continue aspirin 81 mg if bioprosthetic 81 mg PO daily PO daily — Bioprosthetic MV (ACC/AHA 2020 valvular Class IIa lifelong)
13. amoxicillin 2 g 30-60 min before dental procedures 2 g PO PO before procedure — Prosthetic valve + dental procedure with bleeding risk (AHA 2007 endocarditis prophylaxis)

Non-pharmacologic actions:
- Cardiac rehab maintenance phase
- Annual influenza + pneumococcal + COVID-19 vaccination
- Dental cleanings q6 mo with endocarditis prophylaxis
- Valve clinic lifelong follow-up
- Pregnancy counseling (mechanical valve + warfarin teratogenicity)

AVOID / contraindication checks:
- Isolated_vasoconstrictor_AVOID_in_acute_mr_without_afterload_reduction (worsens regurgitant fraction)
- Beta_blocker_AVOID_in_cardiogenic_shock (ACC/AHA 2022)
- Nitrates_caution_with_severe_hypotension (titrate to MAP ≥65 first)
- Nitroprusside_cyanide_risk_if_egfr_lt_30 (use sodium thiosulfate cofactor; alternative agents preferred)
- High_dose_dobutamine_minimize_in_acute_mr (may worsen MR severity)
- LV_only_Impella_complex_in_acute_mr (can worsen MR by altering coaptation; IABP generally preferred bridge per acute MR physiology)
- Routine_VA_ECMO_AVOID_in_acute_mr (no specific benefit shown; surgery is the definitive treatment)
- Doac_AVOID_in_mechanical_valve (warfarin only per ACC/AHA 2020)
- Nsaids_AVOID_in_active_decompensation (worsen renal function + fluid retention)

Monitoring

Regimen monitoring:
- arterial line continuous BP (ACC/AHA 2022 Class I)
- central venous access (ACC/AHA 2022)
- PA catheter for PCWP and v wave trend (helpful in acute MR for response assessment)
- lactate q1-2h (CardShock, Harjola EHJ 2015)
- UOP hourly (SCAI 2019 end-organ perfusion marker)
- serial echo q12-24h post op for valve function (ACC/AHA 2020 valvular)
- continuous telemetry for arrhythmia
- daily BNP and troponin (trend tracks recovery)
- INR daily during warfarin initiation post op (target per valve type)
- blood cultures serial if endocarditis (sterilization tracking)

Setting (outpatient) monitoring:
- Echo at 1 mo + 3 mo + 6 mo + annually
- INR per protocol
- BMP + lipid annually

Follow-up plan: Repeat TTE at 1 wk + 1 mo + 3 mo post-surgery for valve function + LV recovery; cardiac rehab; GDMT if persistent HFrEF; endocarditis prophylaxis per AHA 2007 if prosthetic valve; lifelong follow-up at valve clinic; long-term anticoagulation per valve type (mechanical = warfarin INR per type; bioprosthetic = ASA + 3 mo warfarin + ASA chronic)
- Close-out criterion: Recovery echo, valve clinic follow-up, GDMT, long-term anticoag plan booked

Monitoring phase: A-line, central line, PA catheter for PCWP + V-wave trend, lactate clearance, urine output; continuous telemetry; serial echo q12-24h post-surgery for valve function + LV recovery; daily BNP

Disposition

Current setting: outpatient — 1 mo + 3 mo + 6 mo + annual valve clinic surveillance — confirm valve function + LV recovery + INR control + GDMT optimization + endocarditis prophylaxis + lifelong follow-up

Disposition criteria:
- Stable valve function + LVEF preserved → annual valve clinic follow-up
- Persistent HFrEF → long-term cross-link to cardio.hfref.core.v1 / cardio.hf.core.v1

Escalation triggers (move to higher acuity):
- Symptomatic prosthetic valve dysfunction → emergent valve clinic
- New murmur → echo + valve clinic
- Fever with prosthetic valve → ED + endocarditis workup
- Bleeding on warfarin → ED + reversal

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] STAT TEE confirms papillary muscle rupture (most often posteromedial PM after inferior MI) — mortality ≥80% medical vs <10% surgical (Thompson SHOCK trial sub-analysis)
- [LIFE_THREATENING] IABP placed but persistent shock + worsening lactate + refractory pulm edema → expedite surgery; consider VA-ECMO if surgery not immediately available
- [LIFE_THREATENING] Active infective endocarditis (S. aureus, Strep) + acute severe MR + CS + concurrent sepsis — emergent surgery indication despite operative risk; balance source control vs sepsis stabilization

Citations

- Otto et al ACC/AHA 2020 valvular heart disease guideline (PMID 33342587); Vahanian ESC 2021 valvular heart disease (PMID 34453165); Estévez-Loureiro JACC 2024 IREMMI registry — MitraClip in acute MR with CS (PMID 36440867); SCAI 2022 CS staging (Naidu PMID 35718438) [PMID:33342587](https://pubmed.ncbi.nlm.nih.gov/33342587/)
- Cited evidence (PMID 34453165) [PMID:34453165](https://pubmed.ncbi.nlm.nih.gov/34453165/)
- Cited evidence (PMID 30247738) [PMID:30247738](https://pubmed.ncbi.nlm.nih.gov/30247738/)
- Cited evidence (PMID 36440867) [PMID:36440867](https://pubmed.ncbi.nlm.nih.gov/36440867/)
- Cited evidence (PMID 35718438) [PMID:35718438](https://pubmed.ncbi.nlm.nih.gov/35718438/)

Last reconciled with current guidelines: 2026-05-15.
References
  • Otto et al ACC/AHA 2020 valvular heart disease guideline (PMID 33342587); Vahanian ESC 2021 valvular heart disease (PMID 34453165); Estévez-Loureiro JACC 2024 IREMMI registry — MitraClip in acute MR with CS (PMID 36440867); SCAI 2022 CS staging (Naidu PMID 35718438) — PMID:33342587
  • Cited evidence (PMID 34453165) — PMID:34453165
  • Cited evidence (PMID 30247738) — PMID:30247738
  • Cited evidence (PMID 36440867) — PMID:36440867
  • Cited evidence (PMID 35718438) — PMID:35718438